Cervical cancer is the fourth most common cancer in women. Despite being highly preventable, over 600,000 women were diagnosed and more than 340,000 died from the disease worldwide in 2020. The majority of cervical cancers are caused by infection with human papillomavirus (HPV) and the implementation of HPV vaccines has been shown to reduce the risk of developing invasive cervical cancer. For women with recurrent or metastatic cervical cancer, however, there remains a high unmet clinical need due to lack of standard of care after progression on first-line treatment.
The developer of an investigative medicinal product (IMP) for advanced, recurrent, non-resectable cervical cancer engaged Premier Research to assist with screening and enrollment in a Phase 2 study in Europe.